HKU Study Promises New Treatment For Influenza
"); jQuery("#212 h3").html("

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "http://newsstatic.rthk.hk/audios/mfile_1401896_1_20180615154932.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'http://news.rthk.hk/rthk/en/component/k2/1401896-20180615.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','http://news.rthk.hk/rthk/en/component/k2/1401896-20180615.htm', 'DCS.dcsqry', '' ); } } }); }); });
2018-06-15 HKT 17:53
Hong Kong University researchers say they've achieved a world first in the fight against influenza, by curing infected mice using a doctored version of the flu virus.
Lead researcher Yuen Kwok-yung said this new kind of treatment promises to be more effective than existing drugs like Tamiflu or Relenza, which are only effective when administered within days of the patient falling ill, and for which viruses can quickly develop resistance.
The new treatment effectively turns the flu virus against itself. Researchers cuts away certain key genes from the virus, which prevents it from replicating normally. This 'defective interfering gene' treatment, dubbed DIG3, is therefore resistant to mutation because the virus recognises it as one of its own.
"The cell is being cheated... it's treated as the normal influenza virus. And so we do not expect mutations to develop against the defective interfering genes", Yuen said.
Another researcher, Kelvin To, said their study is the "first time in the world that defective interfering gene has been successfully demonstrated to cure mice from influenza."
"In this study, we have tested H7N7 and H1N1, but we believe that it should theoretically be able to fight against other subtypes of influenza viruses as well," he added.
However, researchers caution that it can take decades of development, clinical trials and adjustments, costing billions of dollars, before the technology can lead to new drugs actually being introduced to the market.
"We have a patent, and we're waiting for investors and companies to develop [the treatment] further in clinical trials et cetera. And we hope that, with the government's emphasis on innovation and technology, there would be money coming in to develop this into a marketable drug one day", Yuen said.
Hong Kong Fund Industry May Double With Tokenised Finance And 24/7 Trading Access
Hong Kong could potentially double the size of its fund industry by moving from legacy infrastructure to token-based fi... Read more
HKMA Alerts Public To Scam Website And Login Screens Posing As Official Site
The Hong Kong Monetary Authority (HKMA) has issued a public alert regarding a fraudulent website and online login scree... Read more
Hong Kong Fintech Promotion Blueprint Indicates 4 Incoming Flagship Projects
The Hong Kong Monetary Authority (HKMA) released the Hong Kong Fintech Promotion Blueprint on 3 February 2025, which sh... Read more
Visa To Enable Cross-Border Payments To 95% Of UnionPay Cardholders In China
At Web Summit Qatar, Visa and UnionPay International (UPI) announced an agreement to enable cross-border money transfer... Read more
HKMA Launches Fintech Blueprint With AI, DLT, Quantum And Cybersecurity Focus
The Hong Kong Monetary Authority (HKMA) published a Fintech Promotion Blueprint to support responsible innovation and f... Read more
How Gaming Giants Are Redefining The Experience Of Paying
Gaming isn’t just a hobby; it’s a global infrastructure challenge. In this episode Vincent Fong (Chief Editor, Fint... Read more


